QUOTED. Andrew Newland.
Executive Summary
Liquid biopsy company Angle recently outlined its strategy to Medtech Insight as it nears regulatory announcements. See what Angle’s CEO Andrew Newland said about it here.
"Well over 90% of patients who die of cancer die from secondary cancer. If you could get a hold of these cells, they could be studied to get all the information needed about the cancer’s spread, and what drugs to use against it.” – Andrew Newland, CEO, Angle
Click here for a free trial of Medtech Insight